Hypertension is a leading cause of non-fatal and fatal cardiovascular complications [1].
Although pharmacological blood pressure-lowering reduces the risk of cardiovascular …

The efficacy of renal denervation (RDN) has been controversial, but recent randomized
sham-controlled trials demonstrated significant blood pressure reductions after RDN in …

Herein, we review interventional peripheral neuromodulatory approaches to reduce blood
pressure (BP), specifically focusing on catheter-based renal denervation (RDN), as well as …

Hypertension is the major risk factor for cardiovascular morbidity and mortality. Matter of fact,
untreated hypertension can worsen the overall health, whereas pharmacotherapy can play …

Abstract The US Food and Drug Administration has approved renal denervation (RDN) as a
new treatment option for hypertension (HT) because it not only has antihypertensive effects …

To overcome uncontrolled hypertension is one of the biggest challenges in Asia and the
globe due to the heterogeneity among different countries [1]. International Society of …

Hypertension is an important risk factor for cardiovascular disease. In the Netherlands, there
are approximately 2.8 million people with hypertension. Despite treatment recommendations …

Studies of renal denervation continue to find a robust antihypertensive effect, especially in
studies wherein medications are withdrawn. Further investigation into mechanisms and …

Purpose of review This review aims to provide an overview of the neural innervation of the
cardiovascular system and present a summary of current autonomic targets for a variety of …

Background Renal denervation (RDN) has emerged in recent years as a possible treatment
for hypertension. The first sham-controlled trial showed a small magnitude and non …